Doximity, Inc. (DOCS) vs PDS Biotechnology Corporation (PDSB)
A side-by-side comparison of Doximity, Inc. and PDS Biotechnology Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 30, 2026. Differences are shown without an overall score or investment verdict.
DOCS
Doximity, Inc.
$26.73HealthcareAt close: Aug 28, 2026, 4:00 PM ET
PDSB
PDS Biotechnology Corporation
$0.21HealthcareAt close: Aug 28, 2026, 4:00 PM ET
Total return — DOCS vs PDSB
growth of $100 · dividends reinvested · last 5yDOCS -49.6% (-12.8%/yr)PDSB -98.0% (-54.4%/yr)DOCS compounded faster over this window
Log scale — wide-divergence pair
DOCS PDSB
DOCS vs PDSB: by the numbers
- •DOCS is the larger company ($5.00B vs $12M market cap).
- •DOCS is profitable (25.48% net margin) while PDSB runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | DOCS | PDSB |
|---|---|---|
| P/E ratio | 31.45 | N/A |
| Forward P/E | 17.28 | N/A |
| P/S ratio | 7.79 | N/A |
| P/B ratio | 5.58 | 3.45 |
| EV / EBITDA | 22.90 | 0.02 |
| FCF yield | 5.86% | N/A |
Profitability
| Metric | DOCS | PDSB |
|---|---|---|
| Gross margin | 88.07% | 0.00% |
| Operating margin | 29.60% | 0.00% |
| Net margin | 25.48% | 0.00% |
| ROE | 18.24% | -372.85% |
| ROIC | 15.35% | -3699.99% |
Growth (annualized)
| Metric | DOCS | PDSB |
|---|---|---|
| Revenue CAGR (5Y) | 21.94% | N/A |
| EPS CAGR (5Y) | 54.32% | N/A |
| FCF CAGR (5Y) | 23.75% | N/A |
| Total return CAGR (5Y) | -20.18% | -57.05% |
Frequently asked
- Is DOCS or PDSB more profitable?
- DOCS runs the higher net margin — DOCS at 25.48% versus PDSB at 0.00%.
- How have DOCS and PDSB total returns compared?
- Over the past 5 years, DOCS delivered -20.18% and PDSB delivered -49.05% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Doximity P/E ratioDoximity ROEPDS Biotechnology ROEDoximity operating marginPDS Biotechnology operating marginDoximity revenue growthPDS Biotechnology revenue growthDoximity free cash flowPDS Biotechnology free cash flow
Doximity & PDS Biotechnology appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 30, 2026.